Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-07-23
Target enrollment:
Participant gender:
Summary
This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed
to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment
in ALK positive stage II-IIIB non-small cell lung cancer after surgical resection with or
without chemotherapy.